A Hugh Mostafid

List of Publications by Year
in descending order

109 papers	5,587 citations	159585 30 h-index	85541 71 g-index
113 all docs	113 docs citations	113 times ranked	4920 citing authors

#	Article	IF	Citations
1	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.9	936
2	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. European Urology, 2018, 73, 111-122.	1.9	627
3	European Association of Urology Guidelines on Nonâ€“muscle-invasive Bladder Cancer (Ta, T1, and) Tj ETQq1 1 0.784314 rgBT /Overlock	1.9	559
4	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. European Urology, 2021, 79, 62-79.	1.9	532
5	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Nonâ€“muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. European Urology, 2017, 72, 801-813.	1.9	205
6	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€”An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132
7	Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Nonâ€“Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations. European Urology, 2010, 57, 607-614.	1.9	117
8	Grading of Urothelial Carcinoma and The New â€œWorld Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016â€• European Urology Focus, 2019, 5, 457-466.	3.1	112
9	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. European Urology, 2020, 78, 893-906.	1.9	112
10	Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. European Urology Focus, 2019, 5, 205-223.	3.1	103
11	Quality Improvement in Multidisciplinary Cancer Teams: An Investigation of Teamwork and Clinical Decision-Making and Cross-Validation of Assessments. Annals of Surgical Oncology, 2011, 18, 3535-3543.	1.5	97
12	EAUâ€“ESMO consensus statements on the management of advanced and variant bladder cancerâ€”an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 2019, 30, 1697-1727.	1.2	96
13	Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-GuÃ©rin or Institutional Standard in Patients with Recurrence of Nonâ€“muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-GuÃ©rin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology, 2019, 75, 63-71.	1.9	96
14	Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 5818-5831.	7.0	86
15	Planning percutaneous nephrolithotomy using multidetector computed tomography urography, multiplanar reconstruction and three-dimensional reformatting. BJU International, 2005, 95, 1280-1284.	2.5	84
16	Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. European Urology, 2018, 74, 10-14.	1.9	78
17	An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. European Urology, 2020, 78, 546-569.	1.9	77
18	Guideline of guidelines: asymptomatic microscopic haematuria. BJU International, 2018, 121, 176-183.	2.5	76

#	Article	IF	Citations
19	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Nonâ€“muscle-invasive Bladder Cancer. European Urology Focus, 2019, 5, 224-241.	3.1	74
20	Risk Stratification Tools and Prognostic Models in Nonâ€“muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. European Urology Focus, 2020, 6, 479-489.	3.1	72
21	BCG immunotherapy for bladder cancerâ€”the effects of substrain differences. Nature Reviews Urology, 2013, 10, 580-588.	3.8	65
22	Therapeutic Options in High-risk Nonâ€“muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-GuÃ©rin. European Urology, 2015, 67, 359-360.	1.9	62
23	Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?. Journal of Urology, 2018, 200, 973-980.	0.4	62
24	Advances in intravesical drug delivery systems to treat bladder cancer. International Journal of Pharmaceutics, 2017, 532, 105-117.	5.2	58
25	Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients. Bladder Cancer, 2018, 4, 395-401.	0.4	55
26	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Nonâ€“muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Nonâ€“muscle-invasive Bladder Cancer Guidelines Panel Study. European Urology Oncology, 2021, 4, 182-191.	5.4	54
27	A core outcome set for localised prostate cancer effectiveness trials. BJU International, 2017, 120, E64-E79.	2.5	48
28	Prevention of bladder cancer incidence and recurrence. Current Opinion in Urology, 2018, 28, 88-92.	1.8	44
29	The selfâ€expanding metallic ureteric stent in the longâ€term management of benign ureteric strictures. BJU International, 2001, 88, 339-342.	2.5	43
30	Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). BJU International, 2012, 109, 1579-1582.	2.5	35
31	Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. European Urology, 2020, 77, 669-670.	1.9	30
32	The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer â€“ a multicentre observational study. BJU International, 2021, 128, 440-450.	2.5	30
33	Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. British Journal of Cancer, 2012, 106, 496-507.	6.4	28
34	BOXITâ€”A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology, 2019, 75, 593-601.	1.9	27
35	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 440-448.	1.6	27
36	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycinâ€C vs surgical management in lowâ€risk nonâ€muscleâ€invasive bladder cancer. BJU International, 2020, 125, 817-826.	2.5	27

#	Article	IF	Citations
37	Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. European Urology Oncology, 2021, 4, 12-19.	5.4	26
38	No â€˜one size fits allâ€™ approach in the management of high-risk non-muscle invasive bladder cancer. Scandinavian Journal of Urology, 2021, 55, 53-53.	1.0	26
39	The responsiveness of the ICSmale questionnaire to outcome: evidence from the ICS-â€˜BPHâ€™ study. BJU International, 2001, 83, 243-248.	2.5	25
40	Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. BJU International, 2006, 97, 509-512.	2.5	25
41	Does urinary cytology have a role in haematuria investigations?. BJU International, 2019, 123, 74-81.	2.5	25
42	Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. European Urology, 2022, 82, 182-192.	1.9	25
43	Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmetteâ€“GuÃ©rin shortage. Current Opinion in Urology, 2020, 30, 365-369.	1.8	23
44	Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 62.e13-62.e20.	1.6	21
45	The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate. BJU International, 2001, 88, 217-220.	2.5	20
46	Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. Journal of Internal Medicine, 2019, 285, 436-445.	6.0	20
47	Emerging Immunotherapy Options for bacillus Calmette-GuÃ©rin Unresponsive Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2019, 202, 1111-1119.	0.4	20
48	A prospective randomized trial of interstitial radiofrequency therapy versus transurethral resection for the treatment of benign prostatic hyperplasia. BJU International, 1997, 80, 116-122.	2.5	18
49	What to do during Bacillus Calmetteâ€“GuÃ©rin shortage? Valid strategies based on evidence. Current Opinion in Urology, 2018, 28, 570-576.	1.8	18
50	Exploring patientsâ€™ experience and perception of being diagnosed with bladder cancer: a mixedâ€methods approach. BJU International, 2020, 125, 669-678.	2.5	18
51	Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness. BMJ Open, 2019, 9, e022268.	1.9	16
52	Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. BMJ Open, 2020, 10, e041005.	1.9	16
53	Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality improvements. Journal of Clinical Urology, 2014, 7, 90-98.	0.1	15
54	Measles, mumps and rubella - the urologist's perspective. International Journal of Clinical Practice, 2006, 60, 335-339.	1.7	14

#	Article	IF	Citations
55	Mesh erosion following laparoscopic incisional hernia repair. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2012, 16, 223-226.	2.0	14
56	So Much Cost, Such Little Progress. European Urology, 2014, 66, 263-264.	1.9	13
57	Diagnostic accuracy of ultrasonography, computed tomography, cystoscopy and cytology to detect urinary tract malignancies in patients with asymptomatic hematuria. World Journal of Urology, 2021, 39, 97-103.	2.2	13
58	IS IT TIME TO REâ€ÐESIGN THE HAEMATURIA CLINIC?. BJU International, 2010, 105, 585-588.	2.5	12
59	Mixedâ€methods approach to exploring patientsâ€™ perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. BJU International, 2019, 124, 408-417.	2.5	12
60	En-bloc resection of bladder tumour as primary treatment for patients with non-muscle-invasive bladder cancer: routine implementation in a multi-centre setting. World Journal of Urology, 2021, 39, 3353-3358.	2.2	12
61	The role of hexylaminolaevulinate in the diagnosis and followâ€up of nonâ€muscleâ€invasive bladder cancer. BJU International, 2010, 105, 2-7.	2.5	11
62	Therapeutic options in the management of intermediateâ€risk nonmuscleâ€invasive bladder cancer. BJU International, 2009, 103, 726-729.	2.5	9
63	Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas BÃ¶hle, Maximilian Burger, et al. EAU Guidelines on Nonâ€“muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447â€“61. European Urology, 2017, 71, e173-e174.	1.9	9
64	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of nonâ€muscleâ€invasive disease. BJU International, 2019, 123, 947-958.	2.5	9
65	Rapid, Low-Cost Dielectrophoretic Diagnosis of Bladder Cancer in a Clinical Setting. IEEE Journal of Translational Engineering in Health and Medicine, 2020, 8, 1-5.	3.7	9
66	What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?. BJU International, 2021, 128, 225-235.	2.5	9
67	IMPROVED DETECTION AND REDUCED EARLY RECURRENCE OF NONâ€MUSCLEâ€INVASIVE BLADDER CANCER USING HEXAMINOLAEVULINATE FLUORESCENCE CYSTOSCOPY: RESULTS OF A MULTICENTRE PROSPECTIVE RANDOMIZED STUDY (PC B305). BJU International, 2009, 104, 889-890.	2.5	8
68	Indication for a Single Postoperative Instillation of Chemotherapy in Nonâ€“muscle-invasive Bladder Cancer: What Factors Should Be Considered?. European Urology Focus, 2018, 4, 525-528.	3.1	8
69	Consensus Definition and Prediction of Complexity in Transurethral Resection or Bladder Endoscopic Dissection of Bladder Tumours. Cancers, 2020, 12, 3063.	3.7	7
70	Do patients with frank haematuria referred under the two-week rule have a higher incidence of bladder cancer?. Annals of the Royal College of Surgeons of England, 2005, 87, 345-347.	0.6	7
71	The Use of the NMP22 BladderChek Test for Bladder Cancer to Optimise Investigations in a One-Stop Haematuria Clinic. British Journal of Medical and Surgical Urology, 2008, 1, 126-130.	0.2	6
72	IDENTIFY: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer: A multicentre cohort study. International Journal of Surgery Protocols, 2020, 21, 8-12.	1.1	6

#	Article	IF	Citations
73	Leydig cell tumour of the testis: a rare cause of male infertility. BJU International, 1998, 81, 651-651.	2.5	5
74	The management of hydronephrosis in patients undergoing TURBT. International Urology and Nephrology, 2007, 38, 483-486.	1.4	5
75	Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.. Journal of Clinical Oncology, 2016, 34, e16016-e16016.	1.6	5
76	Does the Nonurologic Scientific Community Understand Urothelial Bladder Cancer?. European Urology, 2014, 66, 601-602.	1.9	4
77	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Nonâ€“muscle-invasive Bladder Cancer Spectrum. European Urology Focus, 2022, , .	3.1	4
78	Interstitial Radiofrequency Therapy of the Prostate: Results of a Pilot Study. Journal of Urology, 1996, 155, 1946-1949.	0.4	3
79	The testicular 'tumour' of adrenogenital syndrome: an unusual cause of male infertility. BJU International, 1998, 81, 649-650.	2.5	3
80	Radio-Contrast Enhancement of a Urinary Tract Calculus. Urologia Internationalis, 1999, 62, 127-129.	1.3	3
81	Emergency dorsal slit for balanitis with retention. Journal of the Royal Society of Medicine, 2004, 97, 205-206.	2.0	3
82	Case report: differential diagnosis of isolated iliac lymphadenopathy following Bacillus Calmette-GuÃ©rin treatment for high-risk superficial bladder cancer. International Urology and Nephrology, 2007, 39, 1039-1041.	1.4	3
83	Diagnosis and treatment of non-muscle-invasive bladder cancer. Trends in Urology & Men's Health, 2015, 6, 23-27.	0.4	3
84	Time to reâ€evaluate and refine reâ€transurethral resection in bladder cancer?. BJU International, 2016, 118, 9-10.	2.5	3
85	Genetic polymorphisms may explain association between alcohol consumption and bladder cancer risk in East Asian men. Translational Andrology and Urology, 2018, 7, S252-S254.	1.4	3
86	Indications and Complications of Androgen Deprivation Therapy. Seminars in Oncology Nursing, 2020, 36, 151042.	1.5	3
87	Alternating Cystoscopy with Bladder EpiCheckÂ® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. Bladder Cancer, 2021, 7, 307-315.	0.4	3
88	Management of <scp>NMIBC</scp> during <scp>BCG</scp> shortage and <scp>COVID</scp>â€19. Trends in Urology & Men's Health, 2021, 12, 7-11.	0.4	3
89	A novel device for reconstituting and delivering intravesical chemotherapy. BJU International, 2003, 92, 492-492.	2.5	2
90	RE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS. Journal of Urology, 2005, 173, 1433-1433.	0.4	2

#	Article	IF	Citations
91	Neoadjuvant Intravesical Therapy for Nonâ€“muscle-invasive Bladder Cancer: A New Approach for Old Agents?. European Urology, 2020, 78, 863-864.	1.9	2
92	THE BAUS UROLOGICAL CANCER OBSERVATORY. BJU International, 2009, 104, 562-562.	2.5	1
93	The Safe and Economical Care of Ta Bladder Cancer. Urology Practice, 2014, 1, 176-183.	0.5	1
94	T1 High-grade Bladder Cancer: The Search for the Optimal Management Continues. European Urology, 2018, 74, 609-610.	1.9	1
95	Intravesical BCG: where do we stand? Past, present and future. Journal of Clinical Urology, 2019, 12, 425-435.	0.1	1
96	Cystoscopic surveillance for bladder cancer: Learning the lessons forced upon us by the Covid-19 pandemic*. Scandinavian Journal of Urology, 2020, 54, 367-368.	1.0	1
97	Early recurrence and the need for re-resection following Photodynamic diagnosisâ€“assisted Transurethral Resection of Bladder Tumours: Multi-centre real-world experience of the UK PDD Users Group. Journal of Clinical Urology, 2021, 14, 65-72.	0.1	1
98	RE: POSSIBLE MECHANISMS OF ACTION OF TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE ON BENIGN PROSTATIC HYPERPLASIA SYMPTOMS A NEUROHISTOCHEMICAL STUDY. Journal of Urology, 1998, 159, 209-210.	0.4	0
99	Immediate Postoperative Instillation of Intravesical Mitomycin in Theatre: Outcome and Effect on Recurrence of Non Muscle-Invasive Bladder Cancer. Current Urology, 2009, 3, 72-75.	0.6	0
100	Editorial Comment to Maintenance intravesical bacillus Calmetteâ€GuÃ©rin instillation for Ta, T1 cancer and carcinoma inâ€ƒsitu of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group. International Journal of Urology, 2010, 17, 766-767.	1.0	0
101	Predicting Outcomes in Bladder Cancer: Are We Any Good and Could We Do Better?. European Urology, 2015, 68, 254-255.	1.9	0
102	Is 4 days hospital stay post robotic radical cystectomy feasible; A multidisciplinary enhanced recovery program after minimal invasive surgery challenge. Clinical Nutrition ESPEN, 2017, 19, 79.	1.2	0
103	PD36-06 IS FOUR DAYS HOSPITAL STAY AFTER ROBOTIC ASSISTED RADICAL CYSTECTOMY FEASIBLE? A MULTIDISCIPLINARY ENHANCED RECOVERY PROGRAM CHALLENGE. Journal of Urology, 2017, 197, .	0.4	0
104	PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÃ‰RIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL. Journal of Urology, 2017, 197, .	0.4	0
105	Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials. Trials, 2018, 19, .	1.6	0
106	The beginning of the end for asymptomatic microsopic haematuria. Scandinavian Journal of Urology, 2019, 53, 7-7.	1.0	0
107	The inflammatory potential of diet and bladder cancer risk: results from a prospective cohort study. Translational Andrology and Urology, 2019, 8, S491-S492.	1.4	0
108	TULA in recurrent nonâ€muscle invasive bladder cancer. Trends in Urology & Men's Health, 2020, 11, 18-19.	0.4	0

#	Article	IF	Citations
109	En Bloc Resection of Bladder Tumorâ€”Is It the Way Forward?. Frontiers in Surgery, 2021, 8, 685506.	1.4	0